[ Effector Therapeutics raises $38.6M in Series C funding ]

Effector Therapeutics has raised $38.6 million in Series C funding.

Founded in 2012, Effector Therapeutics  is a biopharmaceutical company that researches, develops, manufactures and markets small molecule therapeutics for the treatment of cancer.

The funds will be deployed to advance a broad Phase 2 development program for eFT508, eFFECTOR’s investigational small molecule MNK1/2 inhibitor, including a combination study in colorectal cancer with avelumab* (BAVENCIO), conducted under a clinical collaboration agreement between eFFECTOR, Pfizer and Merck KGaA.

Funding  Series C
Founded  2012
Country  USA
City  San Diego, CA
Founder / CEO  Steve Worland
Deal Size  $38.6M
Investors  Astellas Venture Management
 Pfizer Venture Investments
 Alexandria Venture Investments
 U.S. Venture Partners (USVP)
 Abingworth
 Novartis Venture Fund
 SR One
 The column Group
 Altitude Life Science Ventures
 Sectoral Asset Management
 AbbVie Biotech Ventures
 BioMed Ventures
Previous Investors  U.S. Venture Partners (USVP)
 Abingworth
 Sectoral Asset Management
 Osage University Partners
 Astellas Venture Management
 SR One
 Novartis Venture Fund
 AbbVie Biotech Ventures
 Altitude Life Science Ventures
 Mission Bay Capital
 The Column Group